These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17630543)

  • 1. A new approach for 'deep salvage' trials in advanced HIV infection.
    Lederman MM; Miller V; Weller I; Deeks SG
    AIDS; 2007 Jul; 21(12):1503-6. PubMed ID: 17630543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice.
    Imaz A; Falcó V; Ribera E
    AIDS Rev; 2011; 13(3):180-93. PubMed ID: 21799536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage II.
    Laurence J
    AIDS Read; 1999 Sep; 9(6):370, 372. PubMed ID: 12737125
    [No Abstract]   [Full Text] [Related]  

  • 4. Activism today: the Coalition for Salvage Therapy. Interview with Linda Grinberg. Interview by John S. James.
    Grinberg L
    AIDS Treat News; 1999 Nov; (No 330):2-4. PubMed ID: 11367171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with virologic and metabolic failure.
    Kuritzkes DR
    AIDS Read; 2003 Jun; 13(6 Suppl):S17-22. PubMed ID: 12838743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it time to rethink the expanded-access programs for HIV infection?
    Amorosa V; Tebas P
    J Infect Dis; 2007 Oct; 196(7):974-7. PubMed ID: 17763316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment interruptions in the salvage setting: what have we learned?
    Miller V
    Res Initiat Treat Action; 2003; 9(2):17-9. PubMed ID: 14989202
    [No Abstract]   [Full Text] [Related]  

  • 10. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
    Charpentier C; Laureillard D; Sodqi M; Si-Mohamed A; Karmochkine M; Bélec L; Weiss L; Piketty C
    J Clin Virol; 2008 Oct; 43(2):212-5. PubMed ID: 18760662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D
    AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D; Klimkait T; Telenti A
    Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HIV infection 2007].
    Potthoff A; Brockmeyer N;
    Med Klin (Munich); 2007 Jul; 102(7):531-9. PubMed ID: 17634871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
    Feinberg J; Japour AJ
    Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistant human immunodefiency virus.
    Kozal MJ
    Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to the treatment-experienced patient.
    Gallant JE
    Infect Dis Clin North Am; 2007 Mar; 21(1):85-102, viii-ix. PubMed ID: 17502231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug news.
    Huff B
    GMHC Treat Issues; 2004; 18(9-10):13-5. PubMed ID: 15619787
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA gives salvage therapy testing a push forward.
    Bass E
    AIDS Treat News; 2001 Mar; (362):3-7, 1. PubMed ID: 11569956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.